低剂量阿司匹林是初次全髋关节置换术后静脉血栓栓塞最安全的预防措施吗?
一项基于2012至2025年全国数据库141,334例初次全髋关节置换患者的回顾性研究,按ICM-VTE标准分层为高危和低危队列,经倾向性评分1:1匹配比较低剂量阿司匹林单药与其他抗凝药、联合预防及利伐沙班单药的90天结局。结果显示低剂量阿司匹林单药与更低的深静脉血栓和肺栓塞风险相关,且出血、感染、输血、再入院、急诊就诊和死亡率更低;联合预防则增加VTE和并发症风险,利伐沙班单药与阿司匹林无显著差异。
要点
- 低剂量阿司匹林单药在高危和低危全髋置换患者中均与更低的DVT和PE风险相关。
- 低剂量阿司匹林单药还伴随更低的出血、感染、输血、再入院、急诊就诊和死亡率。
- 联合预防较阿司匹林单药增加VTE和并发症风险,利伐沙班单药与阿司匹林无显著差异。
核心结论
- 在初次全髋关节置换的高危和低危患者中,低剂量阿司匹林单药较其他抗凝策略与更低的VTE和主要术后并发症率相关。
- 研究结果与近期全膝关节置换研究一致,支持ICM-VTE推荐将低剂量阿司匹林作为全髋置换患者各风险分层的安全有效预防选择。
研究设计与样本
- 回顾性队列研究,利用大型全国数据库识别2012至2025年接受初次全髋关节置换的141,334例患者。
- 按ICM-VTE标准将患者分层为高危和低危队列,并进行1:1倾向性评分匹配,比较低剂量阿司匹林单药与其他抗凝药(低分子肝素、直接口服抗凝药或华法林)的90天结局。
- 证据等级为治疗性III级。
主要发现
- 低剂量阿司匹林单药在高危和低危患者中均与显著更低的深静脉血栓和肺栓塞风险相关。
- 低剂量阿司匹林单药还显示出血、感染、输血、再入院、急诊就诊和死亡率降低。
- 联合预防较阿司匹林单药与增加的VTE风险和并发症率相关;利伐沙班单药与低剂量阿司匹林单药相比无显著差异。
关键数值与推荐
- 主要结局为VTE,定义为深静脉血栓或肺栓塞;次要结局包括出血并发症、感染、死亡率及医疗资源利用。
- 亚组分析比较低剂量阿司匹林与联合预防(低剂量阿司匹林加另一种抗凝药)及利伐沙班单药。
临床怎么用
- 对于初次全髋关节置换患者,低剂量阿司匹林单药可作为跨风险分层的VTE预防选择,与ICM-VTE推荐一致。
- 联合预防可能增加VTE和并发症风险,应谨慎使用;利伐沙班单药与低剂量阿司匹林单药在结局上无显著差异。
局限性
- 研究为回顾性数据库分析,证据等级为治疗性III级,可能存在未测量混杂。
- 原文未报告具体数值、置信区间或P值,无法评估效应量大小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) remains a serious complication following primary total hip arthroplasty (THA), prompting routine use of perioperative chemoprophylaxis. In 2022, the International Consensus Meeting (ICM) endorsed low-dose aspirin (LDA) as the preferred VTE prophylactic agent for both hip and knee arthroplasty patients. Prior THA studies lack stratification by VTE risk and direct comparisons between aspirin monotherapy, combination regimens, and alternative anticoagulants. This study aimed to evaluate the safety and efficacy of LDA monotherapy compared to other anticoagulants across high- and low-risk THA cohorts. METHODS: A large national database identified 141,334 patients who underwent primary THA from 2012 to 2025. Patients were stratified into high- and low-risk cohorts based on ICM-VTE criteria. Propensity score matching (1:1) was performed to compare 90-day outcomes between patients receiving LDA monotherapy and those receiving alternative anticoagulants (low-molecular-weight heparin, direct oral anticoagulants, or warfarin). Primary outcomes included VTE, defined as deep vein thrombosis (DVT) or pulmonary embolism (PE). Secondary outcomes included bleeding complications, infections, mortalities, and health care utilization. Subgroup analyses compared LDA with combination prophylaxis (LDA plus another anticoagulant) and rivaroxaban monotherapy. RESULTS: The LDA monotherapy was associated with significantly lower odds of DVT and PE compared to other anticoagulants across both high-risk and low-risk patients. The LDA-only regimens also demonstrated reduced rates of hemorrhages, infections, transfusions, readmissions, emergency department visits, and mortalities. In contrast, combination prophylaxis was associated with increased VTE risk and complication rates compared to LDA alone, while rivaroxaban monotherapy showed no significant differences when compared with LDA. CONCLUSIONS: The LDA monotherapy was associated with reduced rates of VTE and major postoperative complications compared to alternative strategies in both high-risk and low-risk THA patients. These findings align with a recent total knee arthroplasty study and support the ICM-VTE recommendations endorsing LDA as a safe and effective prophylactic option across THA patient risk profiles. LEVEL OF EVIDENCE: Therapeutic level III.
引用
- Tummala S, Areti AS, Liu Y, et al. Is Low-Dose Aspirin the Safest Prophylaxis for Venous Thromboembolism Following Primary Total Hip Arthroplasty? J Arthroplasty. 2026. PMID: 41825492. doi:10.1016/j.arth.2026.02.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。